Aug 13, 2026 earnings call — R&D contract growth and product commercialization
Second-quarter revenue was $5.1 million, up 2% year-over-year and nearly double first quarter revenue.
Revenue $0.0B (est $0.0B) · EPS $-0.04 (est $-0.05)
Key quotes
"The second quarter provided initial evidence that funding and program activity are actually beginning to return to normal and develop."
"ROC SDK, ROC ABIS, and ROC Enroll each generated strong year-over-year revenue growth, and ROC Evidence produced its first commercial revenue."
"We anticipate closing the transaction by the end of the third quarter."
Analyst Q&A 1
government funding and product ramp timelines
Q (Yi Fu Lee · Benchmark): The analyst asked how the government funding recovery looks ahead of the fiscal year end and whether there could be a year-end budget flush. He also asked how ABIS pilots scale to full deployment, the cadence for ROC Watch, how ZTC helps Evidence, the meaning of recent awards, go-to-market hiring, and the company's cash runway.
A: They said the government is signaling recovery with more interactions, quotes and solicitations and must obligate FY '26 monies by September 30, so some spending could accelerate and may trickle into Q4. On ABIS they said the ramp "is about the cadence" of 12 to 18 months, they are not starting from zero and seek multi-million dollar, multi-year beachhead wins; ROC Watch was described as a timing-related spike they are scaling but they will not give formal guidance; ZTC is a key partner and its integration is already paying dividends for Evidence. They said they deployed capital early into people and hardware, expect to convert investments into cash, and ended the quarter with $11.9 million in cash and $14.8 million in working capital with no borrowings.
"So yes, I mean, I think on the liquidity side, we ended the quarter with $11.9 million in cash, $14.8 million in working capital, and no borrowings outstanding on our facility." — Cody Barnes (CFO)